Segment information (Tables)

12 Months Ended

Dec. 31, 2017

Segment Reporting [Abstract]

Revenues

Revenues were as follows (in millions):

	Years ended December 31,
	2017		2016		2015
Product sales:
ENBREL	$	5,433	$	5,965	$	5,364
Neulasta®	4,534		4,648		4,715
Aranesp®	2,053		2,093		1,951
Prolia®	1,968		1,635		1,312
Sensipar®/Mimpara®	1,718		1,582		1,415
XGEVA®	1,575		1,529		1,405
EPOGEN®	1,096		1,282		1,856
KYPROLIS®	835		692		512
Vectibix®	642		611		549
Nplate®	642		584		525
NEUPOGEN®	549		765		1,049
Repatha®	319		141		10
BLINCYTO®	175		115		77
Other	256		250		204
Total product sales	21,795		21,892		20,944
Other revenues	1,054		1,099		718
Total revenues	$	22,849	$	22,991	$	21,662

Geographical information with respect to revenues and long-lived assets

Certain geographic information with respect to revenues and long-lived assets (consisting of property, plant and equipment, net) was as follows (in millions):

	Years ended December 31,
	2017		2016		2015
Revenues:
United States	$	18,029	$	18,326	$	17,167
Rest of the world (ROW)	4,820		4,665		4,495
Total revenues	$	22,849	$	22,991	$	21,662

	December 31,
	2017		2016
Long-lived assets:
United States	$	2,349	$	2,328
Puerto Rico	1,527		1,591
ROW	1,113		1,042
Total long-lived assets	$	4,989	$	4,961

Revenues earned from major customers

Certain information with respect to these customers was as follows (dollar amounts in millions):

	Years ended December 31,
	2017			2016			2015
AmerisourceBergen Corporation:
Gross product sales	$	10,742		$	10,100		$	10,038
% of total gross revenues	31		%	31		%	34		%
% of U.S. gross product sales	37		%	38		%	42		%
McKesson Corporation:
Gross product sales	$	10,625		$	9,710		$	8,766
% of total gross revenues	30		%	30		%	30		%
% of U.S. gross product sales	35		%	34		%	34		%
Cardinal Health, Inc.:
Gross product sales	$	7,049		$	6,520		$	5,045
% of total gross revenues	20		%	20		%	17		%
% of U.S. gross product sales	24		%	24		%	21		%